User:Adam Davis/Sandbox 1: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Adam Davis (talk | contribs) No edit summary |
Adam Davis (talk | contribs) No edit summary |
||
| Line 22: | Line 22: | ||
== Disease == | == Disease == | ||
PPARδ agonists are being investigated as treatments for a number of metabolic disorder and cardiovascular disorders, but have not yet been deployed clinically. Current literature suggests that PPARδ agonists could enhance fatty acid oxidation in skeletal muscle, reduce serum triglycerides, increase serum HDL levels, and enhance weight loss<ref>DOI 10.1210/edrv.20.5.0380</ref>. Though there are some health benefits | PPARδ agonists are being investigated as treatments for a number of metabolic disorder and cardiovascular disorders, but have not yet been deployed clinically. Current literature suggests that PPARδ agonists could enhance fatty acid oxidation in skeletal muscle, reduce serum triglycerides, increase serum HDL levels, and enhance weight loss<ref>DOI 10.1210/edrv.20.5.0380</ref>. Though there are some health benefits associated with PPARα and γ agonists, these drugs also have undesirable side effects including such as edema and weight gain, and carcinogenicity in rodents<ref>DOI 10.1371/journal.pone.0033643</ref><ref>DOI 10.1038/35013000</ref>. If PPARδ agonists are to be used clinically, it is thus important to develop a ligand that does not also bind to the other PPARs. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
